


Amarin CEO on Future of Heart Drug Vascepa

Amarin CEO on Future of Heart Drug Vascepa

[Bloomberg Daybreak: Americas](#)

John Thero, chief executive officer at Amarin, talks about early results for their heart drug Vascepa. David Kotok, chairman and chief investment officer at Cumberland Advisors, joins the conversation on “Bloomberg Daybreak: Americas.”



Watch the video for David Kotok’s conversation with Bloomberg’s Alix Steel and Jason Kelly .

?

Watch the embedded video or at Bloomberg.com:
<https://www.bloomberg.com/news/videos/2018-11-20/amarin-ceo-on-future-of-heart-drug-vascepa-video>

Links to other websites or electronic media controlled or offered by Third-Parties (non-affiliates of Cumberland Advisors) are provided only as a reference and courtesy to our users. Cumberland Advisors has no control over such websites, does not recommend or endorse any opinions, ideas, products, information, or content of such sites, and makes no warranties as to the accuracy, completeness, reliability or suitability of their content. Cumberland Advisors hereby disclaims liability for any information, materials, products or services posted or offered at any of the Third-Party websites. The Third-Party may have a privacy and/or security policy different from that of Cumberland Advisors. Therefore, please refer to the specific privacy and security policies of the Third-Party when accessing their websites.

Sign up for our [FREE Cumberland Market Commentaries](#)

Cumberland Advisors Market Commentaries offer insights and analysis on upcoming, important economic issues that potentially impact global financial markets. Our team shares their thinking on global economic developments, market news and other factors that often influence investment opportunities and strategies.